Dexcom Adds Stryker CFO Glenn Boehnlein to Board
Event summary
- Dexcom appointed Glenn Boehnlein to its Board of Directors, effective September 10, 2026.
- Boehnlein previously served as CFO of Stryker Corporation from 2016 to 2025.
- He brings expertise in financial leadership, capital allocation, and strategic M&A.
- Boehnlein currently serves on the boards of Inogen, Agilent Technologies, and Sutter Health.
The big picture
Dexcom's appointment of Glenn Boehnlein reflects a strategic move to bolster its board with deep MedTech financial expertise amid its long-range growth plans. Boehnlein's background in scaling Stryker's global operations aligns with Dexcom's ambitions in diabetes and metabolic health. His additional board roles at Inogen and Agilent suggest a cross-sector perspective that could inform Dexcom's strategic decisions.
What we're watching
- Strategic Expansion
- How Boehnlein's M&A expertise will influence Dexcom's long-range growth plans.
- Financial Discipline
- Whether Boehnlein's focus on free cash flow generation will impact Dexcom's capital allocation.
- Industry Synergies
- The pace at which Boehnlein's MedTech experience translates to Dexcom's metabolic health initiatives.